Share

Europe’s health policies ‘must change’ with stakeholders leaving their ‘comfort zones’

“Patients are waiting for therapeutic improvement and asking us – while we have good technologies – are we really bringing them the best new drugs? And if we look hard in the mirror the fact is that we are not using technology optimally”, said Dr. Denis Lacombe, EORTC Director. “There needs to be more collaboration, new models…and that means we have to think outside the box.”

Read the entire interview here

Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)